Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 2.4% – Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price dropped 2.4% during mid-day trading on Tuesday . The company traded as low as $6.49 and last traded at $6.56. Approximately 939,641 shares were traded during trading, a decline of 84% from the average daily volume of 5,785,825 shares. The stock had previously closed at $6.72.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on RXRX. KeyCorp dropped their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Leerink Partners decreased their price target on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Needham & Company LLC reduced their price target on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, September 4th. Finally, Jefferies Financial Group lowered their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Performance

The stock has a market capitalization of $1.60 billion, a price-to-earnings ratio of -4.18 and a beta of 0.80. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The company has a fifty day moving average of $6.69 and a two-hundred day moving average of $7.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.05). The firm had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. Recursion Pharmaceuticals’s quarterly revenue was up 30.9% on a year-over-year basis. During the same period in the prior year, the company posted ($0.38) earnings per share. On average, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.58 EPS for the current year.

Insider Activity

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the firm’s stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $8.48, for a total value of $97,070.56. Following the sale, the director now owns 7,155,663 shares of the company’s stock, valued at $60,680,022.24. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $8.48, for a total value of $97,070.56. Following the completion of the sale, the director now directly owns 7,155,663 shares of the company’s stock, valued at $60,680,022.24. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Christopher Gibson sold 30,000 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $7.10, for a total transaction of $213,000.00. Following the transaction, the chief executive officer now owns 758,738 shares in the company, valued at approximately $5,387,039.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 201,682 shares of company stock valued at $1,353,652. 15.75% of the stock is owned by insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several large investors have recently added to or reduced their stakes in RXRX. Green Alpha Advisors LLC increased its position in shares of Recursion Pharmaceuticals by 2.9% during the third quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after purchasing an additional 1,800 shares during the period. Wedmont Private Capital increased its holdings in Recursion Pharmaceuticals by 11.8% in the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after buying an additional 2,000 shares during the period. Interchange Capital Partners LLC increased its holdings in Recursion Pharmaceuticals by 7.3% in the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock valued at $268,000 after buying an additional 2,349 shares during the period. Amalgamated Bank raised its stake in shares of Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock valued at $54,000 after buying an additional 2,459 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth about $26,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.